Y-Intercept (HK)’s Avalo Therapeutics AVTX Stock Holding History

Y-Intercept (HK)’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9	Closed	-$13K	–	958
2022 Q2	$13K	Buy	+9	New	+$12K	﹤0.01%	802

Other funds holding AVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Y-Intercept (HK)'s AVTX Position: Q3 2022 in Review

Y-Intercept (HK) sold out of Avalo Therapeutics (AVTX) in Q3 2022, closing a stake of 9 shares — an estimated $13K sold.

Y-Intercept (HK) first reported a position in AVTX in Q2 2022 and held it in 1 quarter. The position peaked at $13K in Q2 2022. 18 funds tracked by Wall St. Rank hold AVTX as of Q3 2022.

Y-Intercept (HK) reported no remaining Avalo Therapeutics position as of Q3 2022 after selling out during the quarter.
Y-Intercept (HK) sold 9 Avalo Therapeutics shares in Q3 2022, an estimated $13K.
Y-Intercept (HK) first reported a position in Avalo Therapeutics in Q2 2022 and held it in 1 quarter.
Y-Intercept (HK)'s Avalo Therapeutics position peaked at $13K in Q2 2022.
18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2022.

Based on Y-Intercept (HK)'s 13F filing for Q3 2022, filed 14 Feb 2023.